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Abstract
Background: The dosing regimen and indications for many medicines in current use in
neonatology are not well defined. There is a need to prioritise research in this area, but currently
there is little information about which drugs are used in UK neonatal units and the research needs
in this area as perceived by UK neonatologists.
Methods: The Neonatal Clinical Studies Group (CSG) of the Medicines for Children Research
Network (MCRN) undertook a 2 week prospective scoping survey study to establish which
medicines are used in UK neonatal units; how many babies are receiving them; and what clinicians
(and other health professionals) believe are important issues for future research.
Results: 49 out of 116 units responded to at least one element of the survey (42%). 37 units
reported the number of neonates who received medicines over a 2 week period. A total of 3924
medicine-patient pairs were reported with 119 different medicines. 70% of medicine-patient pairs
involved medicines that were missing either a license or dose for either term or preterm neonates.
4.3% of medicine-patient pairs involved medicines that were missing both license and dose for any
neonate. The most common therapeutic gap in need of additional research identified by UK
neonatologists was chronic lung disease (21 responding units), followed by patent ductus arteriosus
and vitamin supplements (11 responding units for both)
Conclusion: The research agenda for neonatal medicines can be informed by knowledge of
current medicine use and the collective views of the neonatal community.
Background
At present there are several drivers for research about med-
icines for neonates. The dosing regimen and indications
for many medications in current use are not well defined.
Up to 90% of babies receiving medication on a neonatal
unit receive unlicensed or off label drugs [1]. The recent
European Union Regulation on Medicines for Paediatric
Use requires studies in neonates to be included in licens-
ing applications for medicines that could be used in the
newborn. This will increase the number of trials in the
newborn. There is a relatively small number of infants,
particularly at gestational ages < 29 weeks. This leads to a
need to prioritise research in this area, so that high quality
research is carried out to answer important clinical ques-
tions from finite funding opportunities. The process of
prioritisation involves an assessment of disease burden
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by the European Medicines Agency (EMEA) for off-patent
medicines. This should be coupled with assessments of
the pattern of medicines use and the licensing status of
medicines [2,3]. Surveys of medication use in neonatal
medicine have been performed before but not recently in
UK.
The Neonatal Clinical Studies Group (CSG) of the Medi-
cines for Children Research Network (MCRN) has a remit
to develop the UK portfolio of neonatal medicines
research. Part of this portfolio will relate to existing med-
icines. The CSG decided to start its portfolio development
work with an examination of medicines use in UK neona-
tal units. The MCRN set up an Extended Neonatal Net-
work (ENN) to support the development and delivery of
the portfolio. The aims of this 2 week prospective scoping
survey study were to examine whether the Extended Neo-
natal Network of the MCRN could be used: i) to establish
which medicines are used in UK neonatal units, and their
relative frequency of use; ii) to determine what clinicians
(and other health professionals) believe are important
issues for future research.
Methods
A scoping survey was devised by the authors (MT, SL, and
DF) and revised by members of the Neonatal and Phar-
macy CSGs of the MCRN. The survey was circulated by e-
mail to 116 neonatal units that are members of the MCRN
Extended Neonatal Network (ENN) and similar groups in
the devolved nations. Two reminders were sent by e-mail.
The two week data collection period occurred at the con-
venience of each Unit (December 2007  April 2008). The
units were characterised by the level of care that they pro-
vide and their location within the UK. Medicines were
grouped by clinical indications. Each unit counted the
number of neonates who received each medicine giving a
number of medicine-patient pairs.
The nature of future research will depend on which infor-
mation is currently not available to prescribers. In the UK
the standard source of dosing information is the British
National Formulary for Children (BNFC). This well-estab-
lished formulary meets WHO standards for national for-
mularies and is based on a broad range of expert opinion.
The BNFC provides dosage information and indicates
when information about medicine is not supported by a
marketing authorisation, what the BNFC describes as "not
licensed". BNFC 2007 was used to determine whether a
medicine was "not licensed", and as a reference for doses,
since it was the edition available to prescribers at the time
of the survey. Medicine-patient pairs were classified
according to the presence or absence of each of the follow-
ing criteria: licensed in preterm neonates; licensed in term
neonates; dose provided for preterm neonates; dose pro-
vided for term neonates. Blood products were excluded
from the survey. Intravenous electrolyte supplements and
parenteral nutrition were reported inconsistently and not
included in the results.
Therapeutic gaps identified by respondents were classified
by two investigators (MT, DH) and any differences
resolved by discussion.
This survey was conducted as a service evaluation and so
did not require consideration by a Research Ethics Com-
mittee: this decision was made by the authors and we did
not seek the opinion of an Ethics Committee on this
point.
Results
Drugs Prescribed on Neonatal Units
Of the 116 units contacted, 45 units indicated which med-
icines they prescribed over a 2 week period with 37 report-
ing how many babies received each medicine during a 2
week period. The level of care provided by each unit and
its location within the UK are given in Table 1 for
responders and non-responders. The characteristics did
not differ between responders and non-responders (chi-
squared test, not significant). In total 3924 medicine-
patient pairs were reported by the units, using 119 differ-
ent medicines. The drugs prescribed to the greatest
number of neonates were gentamicin (n = 417), ben-
zylpenicillin (n = 350), vitamin K (n = 332), caffeine (n =
249) and dalivit (n = 242). 28% of medicine-patient pairs
over the 2 weeks survey period had complete information
available, i.e. licenses for use in term and preterm
neonates with doses for both groups (Table 2). On the
other hand 4.3% of medicine-patient pairs lacked both
licences and doses in both term and preterm neonates
(Table 2). This latter group included medicines such as
chlorhexidine (n = 95) and dexamethasone (n = 11).
Excluding medicines whose license status was unclear
(including heparin, hydrocortisone, phenytoin), a total of
70% of medicine-patient pairs had incomplete data for at
least one criterion (Table 2).
Therapeutic Gaps Identified
37 units suggested one or more therapeutic gaps, provid-
ing 162 suggestions in total. Therapeutic gaps were
grouped by indication and are shown in Figure 1. The
most common therapeutic gap was chronic lung disease
(raised by 21 responding units), followed by patent duc-
tus arteriosus and vitamin supplements (n = 11 for both).
Full results for all aspects of the survey are available from
the Extended Neonatal Network on request
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The results of this survey are comparable with recent
results from the USA [4]. For example the most frequently
prescribed medications on neonatal units in the USA were
ampicillin and gentamicin [4]. 28% of the medicine-
patient pairs involved medicines that were reported to
have licenses and doses for both term and preterm
neonates. This represents a high number of prescriptions
for a relatively small number of medicines (mainly benzyl
penicillin and gentamicin). The fact that 70% of medi-
cine-patient pairs reported during the scoping exercise
involved medicines that were lacking at least one piece of
information suggests that there is a substantial research
agenda in this area.
The methodology used here is simple, was acceptable to a
range of neonatal units and provides a novel approach to
estimating the impact of licensing status. The ENN pro-
vides a useful way to access UK neonatologists. One
approach to assessing the impact of licensing status is to
count the number of licences for neonatal medicines. For
example among the new molecular entities licensed for
use in a paediatric population in the US between 1998
and 2002 only 2% were licensed for use in the newborn
period [5]. Our methodology extends this approach by
estimating the extent of medicines use in neonates that
falls under a marketing authorisation and the extent to
which medicines use is not covered by a marketing
authorisation. A repeat survey in several years time would
indicate how changes in the regulatory framework, such
as the EU regulation, have impacted on patients.
Clinicians are aware of gaps in the therapies they can offer.
This will help inform the future direction of neonatal
pharmacological research. One exemplar is the "The New-
born Drug Development Initiative", which was organised
in the USA by the FDA and NIH Institute for Child Health
and Human Development. This collaboration developed
a process for deciding which drugs were most in need of
study in this population (taking account of the nature of
disease, outcome, drug characteristics, feasibility, meth-
odology and ethics) [6]. Based on this work, criteria have
been established for the investigation of a drug in the US
neonatal population. The information we have gathered
Table 1: Characteristics of units that did and did not respond to the survey.
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Each cell includes the number of units in that category and the percentage of responders and non-responders for that category. Level 1 Units 
provide Special Care but do not aim to provide any continuing High Dependency or Intensive Care. This term includes units with or without 
resident medical staff. Level 2 Units provide High Dependency Care and some short-term Intensive Care. Level 3 Units provide the whole range of 
medical neonatal care but not necessarily all specialist services such as neonatal surgery.
Table 2: Medicine-patient pairs classified according to information given in the BNFC 2007 about licensing status and dosage.
Licensing and dosage status according to BNFC 2007 Number of medication- % of Total
Licensed in preterm Licensed in term Dose in preterm Dose in term patient pairs in each category Medication-patient pairs
No No No No 167 4.3
No No No Yes 697 18
No No Yes Yes 242 6.2
No Yes No Yes 50 1.3
Yes Yes No No 388 9.9
Yes Yes No Yes 1174 30
Yes Yes Yes Yes 1115 28
Unclear Unclear - - 91 2.3
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stakeholders (e.g. parents, professionals, funders and reg-
ulators).
The limitations of this work include the incomplete
response rate. This arose due to the lack of time among
busy professionals to complete an unfunded survey. We
acknowledge that the units who did respond may poten-
tially represent a biased subset of units. However, we
believe that the response rate was sufficient to yield a rep-
resentative range of medicines used in this patient group.
Our estimate of the extent of medicines use that lacks
information relevant to prescribers is likely to reflect the
true number of medicines requiring more information.
We are also aware that the BNFC is not the only source of
information about licensing status and dosing available.
However, the study was designed and carried out through
the UK's MCRN and the BNFC is well recognised, widely
available, and is the national formulary of UK MCRN
units. Comparisons with other sources would have
detracted from our aim of contributing to UK prioritisa-
tion. The denominator in this study is the number of med-
icine-patient pairs on a neonatal unit over a 2 week
period. The 2 week period varied between units. The
number of units, an increased response rate due to the
flexibility of the design and the random nature of admis-
sions to neonatal units are likely to have outweighed the
potential for bias introduced by the lack of a standardised
time point for the start of data collection. Future work
could include an estimate of the number of neonates.
However, that would introduce the need to standardise
for variation between units in admission criteria and for
variation in the gestational age profile.
We have presented a summary of the data. The results also
indicate which units use which medicines and the likely
numbers of neonates in each unit who use each medicine.
This information will facilitate research by allowing the
rapid identification of units who might be interested in a
particular research project. We anticipate that similar
studies will be conducted by national bodies across
Europe. These studies will facilitate international cooper-
ation in areas of common need as well as national priori-
tisation.
Conclusion
To date, the agenda about research into medicines for
neonates has been informed by the interests of individual
investigators and funded on the basis of the quality of
individual trials. Our results raise the possibility that the
research agenda can also be informed by the extent of
medication use and the collective views of the neonatal
community. We speculate that this will facilitate rational
priority setting by directing the community towards
neglected areas (such as Vitamin supplements) and be rel-
evant to decisions about funding and collaboration at
national and international levels.
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Number of therapeutic gaps for each indicationFigur  1
Number of therapeutic gaps for each indication. 
Graph of groups of identified therapeutic gaps against 
number of units who identified them. The abbreviations are: 
CLD, chronic lung disease; PDA, patent ductus arteriosus; 
GI, Gastrointestinal; NAS, neonatal abstinence syndrome.
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